Product Categories and Disease Areas
Expertise across complex therapies and real-world care pathways.
We operate across the full treatment ecosystem, from product to real-world care.
Our work focuses on managing regulatory and operational complexity while maintaining what matters most: patient safety, product integrity, and reliable execution in real-world healthcare settings.
As clinical and commercial landscapes evolve, the range of product types and therapeutic areas continues to expand. From investigational medicines and advanced therapies to specialty drugs, diagnostics, and devices, each comes with distinct regulatory frameworks, handling requirements, and care pathways.
What defines Komtur is not only the ability to move products, but a deep understanding of the environments in which they are used. We connect manufacturers, hospitals, investigators, pharmacists, patient support structures, and authorities into coordinated and compliant access pathways.
This perspective goes beyond distribution. It enables earlier risk identification, more efficient onboarding, and sustained access across the full product lifecycle.
Tell us what you're looking for and we'll route your enquiry to the right team.
Whether it's a comparator, ancillary supply, unlicensed medicine, named patient request or a specific product requirement, we'll review your enquiry and respond with the most appropriate solution.
Tell us what you're looking for and we'll route your enquiry to the right team
Whether you're planning market entry, managing ongoing supply, responding to a shortage, designing an access programme or exploring a commercial partnership, our specialists are here to help.
"In practice, no two therapies behave the same. Each requires a tailored approach across regulation, logistics, and care delivery to ensure reliable patient access."
Core Product Categories
Experience across high-value, high-complexity product types.
These categories define the product types we manage across clinical development, hospital care, and post-approval access.
Each comes with distinct regulatory requirements, handling conditions, and operational constraints that must be addressed to ensure safe and reliable delivery.
Investigational Medicinal Products (IMP)
Investigational Medicinal Products (IMP)
Clinical trial supply requires precise coordination across protocols, countries, and site-level execution.
Investigational Medicinal Products (IMP)
Medicinal products under investigation in clinical trials to assess safety, efficacy, and dosing.
Execution depends on protocol adherence, regulatory alignment, and reliable site delivery across multiple jurisdictions.
Cell & Gene Therapy (ATMPs)
Cell & Gene Therapy (ATMPs)
Delivery depends on strict control of identity, timing, and site readiness at every step.
Cell & Gene Therapy (ATMPs)
Advanced therapies based on genes, cells, or engineered tissues, governed by specialised regulatory frameworks.
Chain-of-identity, cold chain integrity, and exact coordination with clinical sites are critical for safe and compliant administration.
Nutraceuticals
Nutraceuticals
Regulatory classification and permitted use vary widely between markets and intended applications.
Nutraceuticals
Products derived from food sources providing health or wellness benefits.
Use in clinical or access contexts depends on local regulatory acceptance and integration into care pathways.
Diagnostic Medical Devices
Diagnostic Medical Devices
Accurate data depends on seamless integration of diagnostics into clinical workflows and study design.
Diagnostic Medical Devices
Devices used to identify, stratify, or monitor patients during treatment or trials.
Operational success relies on correct deployment, training, and alignment with clinical and data collection processes.
Controlled Substances
Controlled Substances
Strict regulatory controls require secure handling, documentation, and authority coordination across all markets.
Controlled Substances
Medicinal products subject to legal restrictions due to risk of misuse or diversion.
Compliance depends on controlled storage, transport, and documentation aligned with local regulatory frameworks.
Ancillary Medication
Ancillary Medication
Protocol alignment and local clinical practice must be balanced to ensure safe and compliant use.
Ancillary Medication
Medicines used alongside investigational treatments to support safety or protocol requirements.
Variability across sites and countries requires careful alignment with protocol design and clinical practice standards.
Placebo
Placebo
Matched presentation is critical to maintain blinding and avoid bias in trial outcomes.
Placebo
Inactive products designed to match investigational or comparator treatments.
Blinding integrity depends on exact matching in appearance, handling, and documentation. Even minor inconsistencies can compromise trial validity.
Therapeutic Medical Devices
Therapeutic Medical Devices
Effective use depends on site readiness, training, and integration into treatment pathways.
Therapeutic Medical Devices
Devices delivering treatment through mechanical, physical, or digital means.
Implementation requires coordination across logistics, training, and clinical adoption to ensure safe and consistent use.
Veterinary Drugs
Veterinary Drugs
Separate regulatory frameworks and supply chains require distinct handling and compliance approaches.
Veterinary Drugs
Medicinal products used for the treatment or prevention of diseases in animals.
Where applicable, supply must align with veterinary-specific regulations and distribution channels.
Comparators
Comparators
Sourcing must ensure traceability, consistency, and availability across markets with varying supply constraints.
Comparators
Approved medicinal products used as reference treatments in clinical trials.
Availability, documentation, and cross-border sourcing complexity directly impact trial timelines and regulatory compliance.
Commercial and Post-Approval Product Categories
Products supplied in approved and market access contexts.
These categories cover products supplied in approved and market access contexts, including early access, named patient programmes, and ongoing commercial distribution.
Execution in these settings requires alignment with local regulation, reimbursement frameworks, and long-term supply continuity.
Biosimilars
Biosimilars
Adoption depends on regulatory acceptance, clinical confidence, and structured market access pathways.
Biosimilars
Biologic medicines highly similar to approved reference products.
Successful use requires alignment across regulatory documentation, stakeholder acceptance, and controlled integration into clinical practice.
Generics
Generics
Supply stability and substitution dynamics must be managed across pricing and reimbursement pressures.
Generics
Medicinal products equivalent to originators following patent expiry.
Availability, sourcing reliability, and local substitution rules directly impact treatment continuity and access.
Branded Drugs
Branded Drugs
Market access, distribution control, and lifecycle management vary significantly across regions.
Branded Drugs
Originator medicines approved for clinical use and protected by intellectual property rights.
Post-launch success depends on controlled distribution, regulatory alignment, and continuity across diverse healthcare systems.
Orphan & Ultra-Orphan Drugs
Orphan & Ultra-Orphan Drugs
Access depends on navigating fragmented regulations, small patient populations, and limited supply.
Orphan & Ultra-Orphan Drugs
Access depends on navigating fragmented regulations, small patient populations, and limited supply.
Disease Areas
Real-world expertise across high-impact and hard-to-reach therapy areas.
These areas represent where sourcing, access, and distribution must perform under real-world conditions.
Many therapy areas overlap in practice. Effective execution requires operating across disease boundaries where products, patients, and care pathways intersect.
- Cardiology and Metabolic Diseases
- Dermatology
- Endocrinology and Rare Metabolic Diseases
- Gastroenterology and Hepatology
- General Medicine and Emergency Care
- Hematology
- Immunology and Autoimmune Diseases
- Infectious Disease
- Neurology
- Ophthalmology
- Oncology
- Otolaryngology and Balance Disorders
- Psychiatry and Behavioral Disorders
- Pulmonology (Respiratory)
- Reproductive Medicine and Gynecology
- Rheumatology and Orthopedics
- Urology and Nephrology
Beyond the Product
Supporting the broader realities of patient care and product quality
Therapy does not exist in isolation. Real-world outcomes depend on whether patients remain on treatment and whether product quality is maintained throughout the lifecycle.
Non-product factors such as adherence and quality events often determine success in practice.
Quality of Life and Social Circumstances
Quality of Life and Social Circumstances
Clinical trial supply requires precise coordination across protocols, countries, and site-level execution.
Quality of Life and Social Circumstances
Patient outcomes depend not only on therapy, but on the ability to start and stay on treatment.
Barriers such as access limitations, lack of education, or social circumstances can interrupt care. Addressing these factors requires coordination across patient support, access pathways, and real-world delivery models.
Product-Related Issues
Product-Related Issues
Quality events must be managed quickly and compliantly to protect patients and maintain supply continuity.
Product-Related Issues
Deviations, complaints, recalls, and product quality issues are an inherent part of pharmaceutical operations.
Effective handling requires structured processes, regulatory coordination, and rapid response to minimise risk to patients while maintaining compliant supply.
Explore our Service Areas
From early development to post-launch delivery, we deliver integrated solutions that align product and patient journeys. Built to meet specific challenges across the pharmaceutical lifecycle. Designed to help our partners bring therapies to market efficiently, compliantly, and with patients in mind.